Genetic distinctions between autoimmune hepatitis in Italy and North America

Table 1 Clinical and biochemical parameters of the studied groups at baseline.

Features	Italian type 1 AIH (57 patients)	Italian type 2 AIH (17 patients)	North American type 1 AIH (149 patients)
Gender (m/f)	7/50	2/15	27/122
Age (yr)	38 (15–76)	18 (8–34)	47 (13–81)
AST (×UNL)	10.9 (0.5–56)	4.7 (1.5–5.1)	9.5 (0.5–66)
ALP (×UNL)	1.1 (0.2–4.56)	1.5 (0.6–4.4)	0.91 (0.6–6)
Bilirubin (mg/dL)	1.3 (0.2–26)	3.8 (0.9–4.3)	1.9 (0.3–29)
Albumin (g/L)	37 (24–46)	40 (19–48)	32 (15–42)
g-Globulin (g/L)	23 (10–59)	22 (13–48)	29 (4–62)
IgG (mg/dL)	2592 (1 260–6 948)	2600 (1 530–4 212)	2460 (248–7 200)
IgA (mg/dL)	301 (40–963)	346 (30–643) 2	90 (6–1 870)
IgM (mg/dL)	200 (75–597)	307 (150–577)	228 (28–1 400)
ANA positivity	34 (60%)	0	113 (76%)
SMA positivity	44 (77%)	0	111 (74%)
LKM1 positivity	0	16 (94%)	0
LC1 positivity	0	4 (23%)	Not tested

Data are shown as the median value (range). AST: serum aspartate aminotransferase level. ALP: serum alkaline phosphatase level. ANA: anti-nuclear antibodies. SMA: smooth muscle antibodies. LKM1: liver kidney microsome antibodies type 1. LC1: liver cytosol antibodies.